Radar · Genomics in United States
Best Genomics Companies in United States
The 2583 best Genomics companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Freenome Health.
By Riya SenguptaFinancials
2583companies tracked
$64.9Bdisclosed funding
13unicorns
1376have raised
The 2,583 Genomics companies tracked across the United States represent one of the most heavily capitalized science sectors in the country, with $64.9B in disclosed funding and 13 unicorns built on the premise that sequencing is becoming infrastructure. This directory ranks them by disclosed equity funding and recent funding momentum, so you can cut straight to who's actually pulling capital.
The revenue picture is grounded. Across 33 validated filers, the combined pool hits $4.7B, with a median of $33M per company and median growth sitting at a flat -1% YoY. But averages lie. Baxalta Inc booked $1.5B in revenue. Guardant Health, Inc. posted $302M, up 48% year over year. Invitae Corp filed $487M, though it slid 6%. And the net income outliers are stark: Baxalta Inc and Fulgent Genetics each cleared 11x the sector's $13M median. The global market was valued around $24.3B in 2021 and is forecast to reach $85.1B by 2030 at a 16.37% CAGR, driven by falling sequencing costs and rising demand for personalized medicine. I'd note that hot themes right now, from direct-to-consumer genomics to pharmacogenomics, are pulling coverage and capital alike. So the floor is rising, even where growth hasn't caught up yet.
Sources & further reading
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
- USPTO issues flurry of new rules to implement 'America Invents Act'
- Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease
FLIAR INTELLIGENCE · GENOMICS × UNITED STATES
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
84%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
690kcombined LinkedIn audience
48%of audience held by top 3
9companies hiring publicly (12 mo)
Ranked: Best Genomics companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Caris Life Sciences 🦄 Developer of panomic disease profiling technologies for cancer precision medicine 78Moat top 15%Funding top 17%Product top 19%Market top 28% All 9 signals ▾Moattop 15% Fundingtop 17% Producttop 19% Markettop 28% Innovationtop 38% Growthtop 40% Newstop 43% Techtop 44% Globaltop 46% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $1.1B across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $1.1B | 14 mo ago | 1,339 | — | WordPress Site EditorCart FunctionalityWordPress+19 | 7 signals ▼22% Earnings · IPO | — | — |
| 2 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | WordPress Site EditorWordPressMySQL+12 | 5 signals Funding · Capital raise · Leadership | — | — |
| 3 | Guardant Health Developer of digital sequencing technology for cancer detection 90Patents top 14%Funding top 15%Innovation top 17%Moat top 19% All 13 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Moattop 19% Markettop 23% Techtop 23% Newstop 29% Growthtop 30% Producttop 35% Fin. healthtop 36% Partnerstop 41% Globaltop 45% Talenttop 46% Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $557M | 7 mo ago | 1,351 | Amirali Talasaz Co-founder and Co-Chief Executive Officer | WordPressBugHerdApple iCloud Mail+25 | 25 signals ▲56% Earnings · Announcements · Regulatory | 996 patents Liquid biopsy cfDNA sequencing and analysis for cancer detection and monitoring | 1 launch · 1 partnership |
| 4 | eGenesis Developer of a gene transplantation platform for humanizing pig cells 67Funding top 20%Product top 21%Patents top 23%Moat top 28% All 11 signals ▾Fundingtop 20% Producttop 21% Patentstop 23% Moattop 28% Innovationtop 32% Growthtop 38% Talenttop 38% Techtop 40% Marketbottom 44% Globalbottom 44% Newsbottom 18% Funding: Raised $481M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Product: 5 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 67/100 | $481M | 21 mo ago | 94 94 → 153 (+63%) · sector median +17% | Luhan Yang Co-Founder | Craft CMSApple iCloud MailMicrosoft 365+17 | — | 61 patents Genetically engineered livestock for xenotransplant organ compatibility | 1 award |
| 5 | Lexicon Pharmaceuticals Developer of small molecule drugs for diffrent health diseases 76Funding top 20%Patents top 24%Talent top 28%Growth top 30% All 11 signals ▾Fundingtop 20% Patentstop 24% Talenttop 28% Growthtop 30% Techtop 35% Innovationtop 40% Markettop 41% Fin. healthtop 41% Moattop 44% Newstop 45% Globalbottom 44% Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $381M | 4 mo ago | 135 135 → 284 (+110%) · sector median +17% | Ivan Cheung Board of Directors | DrupalApple iCloud MailPHP+31 | 15 signals ▼35% Announcements · Capital raise · Acquisition | 1,211 patents Patents concentrated in chemistry & materials | — |
| 6 | Maze Therapeutics Developer of genetic bio-markers in neurological, metabolic, and renal diseases 53Funding top 22%News top 24%Growth top 31%Moat top 46% All 9 signals ▾Fundingtop 22% Newstop 24% Growthtop 31% Moattop 46% Marketbottom 49% Techbottom 49% Fin. healthbottom 44% Talentbottom 40% Globalbottom 39% Funding: Raised $381M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 9 BI events in 12 mo (of 23 tracked, 5 types) · +125% YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $381M | 9 mo ago | 111 111 → 155 (+40%) · sector median +17% | Jason Coloma CEO | WordPressApple iCloud MailMicrosoft 365+16 | 9 signals ▲125% Earnings · Funding · IPO | — | — |
| 7 | Delfi Diagnostics Provider of DNA sequencing for cancer detection 67Funding top 17%Patents top 24%AI top 28%Moat top 28% All 11 signals ▾Fundingtop 17% Patentstop 24% AItop 28% Moattop 28% Innovationtop 32% Talenttop 42% Growthtop 48% Marketbottom 49% Techbottom 47% Globalbottom 36% Newsbottom 33% Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $332M | 6 mo ago | 197 | Victor Velculescu Founder and Board of Directors | WordPressApple iCloud MailMySQL+16 | — | 52 patents Non-invasive cancer detection and monitoring via cell‑free DNA fragmentation profiling | 1 job opening · 1 partnership · 3 awards |
| 8 | Arbor Biotechnologies Provider of genomic technologies and drug discovery platform 82Patents top 15%Innovation top 17%Funding top 19%Growth top 25% All 12 signals ▾Patentstop 15% Innovationtop 17% Fundingtop 19% Growthtop 25% Producttop 25% Moattop 26% Talenttop 28% AItop 45% Markettop 47% Globalbottom 42% Techbottom 36% Newsbottom 27% Patents: 372 patents matched (strict assignee match) · 307 filings since 2022 vs 65 in 2017-21 Innovation: 372 patents (top 6% of patent-holders) · 307 filings since 2022 vs 65 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $300M | 7 mo ago | 117 117 → 102 (-13%) · sector median +17% | David Scott Co-Founder | — | — | 372 patents CRISPR nucleases and reverse transcriptase enzymes for genome editing platforms | 2 partnerships |
| 9 | Sirnaomics Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease 80Patents top 14%Funding top 15%Innovation top 17%Growth top 28% All 9 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Growthtop 28% Moattop 35% Markettop 46% Talentbottom 49% Globalbottom 48% Newsbottom 21% Patents: 277 patents matched (strict assignee match) · 191 filings since 2022 vs 63 in 2017-21 Funding: Raised $267M across 14 rounds · 14 rounds over 19 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $267M | 9 mo ago | 88 | Patrick Lu President and CEO | — | — | 277 patents siRNA therapeutics and nanoparticle delivery systems for cancer and viral diseases | 1 launch |
| 10 | Aspen Neuroscience Provider of genomic-based personalised pluripotent stem cell therapy 64Funding top 17%Patents top 23%Moat top 28%Innovation top 33% All 10 signals ▾Fundingtop 17% Patentstop 23% Moattop 28% Innovationtop 33% Growthtop 35% Newstop 45% Marketbottom 49% Talentbottom 49% Techbottom 46% Globalbottom 45% Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $224M | 6 mo ago | 94 | Damien Mcdevitt President | WordPress Block EditorWordPressMySQL+19 | — | 57 patents Patents concentrated in computing, sensing & instrumentation | — |
| 11 | GreenLight Biosciences 🦄 Developer of a platform for RNA-based products for life science industry 69Funding top 23%Growth top 23%Patents top 24%Innovation top 29% All 11 signals ▾Fundingtop 23% Growthtop 23% Patentstop 24% Innovationtop 29% Talenttop 41% Moattop 42% Fin. healthtop 47% Markettop 48% Techbottom 44% Globalbottom 42% Newsbottom 40% Funding: Raised $215M across 12 rounds · 12 rounds over 13 yrs (0.9/yr) Growth: Headcount 163 → 287 (+76%) across vintages · Revenue +325% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $215M | 14 mo ago | 287 287 → 183 (-36%) · sector median +17% | Andrey Zarur Co-Founder & CEO | WebflowTypekitGoogle Font API+12 | — | 311 patents RNAi-based biopesticides and lipid‑encapsulated RNA delivery for crop protection | — |
| 12 | CAMP4 Provider of a drug prediction and development tool for researchers 53Funding top 17%Growth top 37%Moat top 39%Talent top 41% All 9 signals ▾Fundingtop 17% Growthtop 37% Moattop 39% Talenttop 41% AItop 45% Marketbottom 41% Globalbottom 37% Techbottom 26% Newsbottom 20% Funding: Raised $180M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Growth: Headcount 37 → 62 (+68%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $180M | 9 mo ago | 62 62 → 62 (+0%) · sector median +17% | Josh Mandel-Brehm CEO | WordPressApple iCloud MailMicrosoft 365+13 | — | — | — |
| 13 | Tango Therapeutics Developer of drugs for the treatment of cancer 72Funding top 21%News top 21%Growth top 24%Talent top 33% All 10 signals ▾Fundingtop 21% Newstop 21% Growthtop 24% Talenttop 33% Fin. healthtop 41% Techtop 44% Markettop 45% Partnerstop 45% Moatbottom 49% Globalbottom 37% Funding: Raised $165M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) News: 17 BI events in 12 mo (of 35 tracked, 6 types) · +240% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $165M | 7 mo ago | 140 140 → 157 (+12%) · sector median +17% | Barbara Weber Md President and CEO | DrupalPHPZURB Foundation+21 | 17 signals ▲240% Earnings · Funding · Leadership | — | — |
| 14 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | 122 | Jim Collins Co-Founder | DrupalPHPSalesforce+24 | 3 signals ▼75% Earnings · Announcements | — | — |
| 15 | Atlas Data Provider of cloud-based data storage solutions utilizing DNA as a highly durable, low-cost, and permanent… 29Funding top 26%Moat top 40%Talent bottom 49%Tech bottom 45% All 6 signals ▾Fundingtop 26% Moattop 40% Talentbottom 49% Techbottom 45% Marketbottom 35% Globalbottom 33% Funding: Raised $155M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Soonicorn · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $155M | 13 mo ago | — | Varun Mehta CEO | WordPress Block EditorWordPressMySQL+19 | — | — | — |
| 16 | QurAlis Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS) 64Funding top 20%Patents top 23%Innovation top 25%Growth top 26% All 10 signals ▾Fundingtop 20% Patentstop 23% Innovationtop 25% Growthtop 26% Moattop 32% Talenttop 41% Techbottom 43% Globalbottom 42% Marketbottom 36% Newsbottom 22% Funding: Raised $144M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Patents: 69 patents matched (strict assignee match) · 62 filings since 2022 vs 7 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 9 mo ago | 38 38 → 87 (+129%) · sector median +17% | Kasper Roet Founder & CEO | WordPressApple iCloud MailMicrosoft 365+17 | — | 69 patents Antisense oligonucleotide therapeutics targeting UNC13A for neurological disease treatment | — |
| 17 | Precision BioSciences Developer of gene editing therapies to treat rare genetic diseases 57Product top 19%Funding top 21%Moat top 32%Patents top 36% All 11 signals ▾Producttop 19% Fundingtop 21% Moattop 32% Patentstop 36% Newstop 38% Markettop 39% Techtop 41% Innovationtop 42% Growthbottom 47% Globalbottom 42% Fin. healthbottom 39% Product: 3 distinct product lines · Company stage: Public Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $136M | 3 mo ago | 236 | — | DrupalApple iCloud MailMicrosoft 365+23 | 3 signals ▲50% Regulatory · Earnings · Capital raise | 68 patents Therapeutic genome editing using engineered meganucleases and engineered T‑cell therapies | 1 launch |
| 18 | Mission Bio Provider of single cell multiomics platform for genotypic and phenotypic analysis 82Funding top 18%Tech top 21%Innovation top 25%Product top 25% All 10 signals ▾Fundingtop 18% Techtop 21% Innovationtop 25% Producttop 25% Talenttop 28% Moattop 31% Growthtop 37% Markettop 44% Globalbottom 39% Newsbottom 27% Funding: Raised $120M across 11 rounds · 11 rounds over 11 yrs (1.0/yr) Tech: 55 technologies across 6/8 capability areas · Cloud: Cloudflare, Vercel rank vs industry peers · Fliar Intelligence Index 82/100 | $120M | 10 mo ago | 109 109 → 89 (-18%) · sector median +17% | Adam Sciambi Co-Founder & Chief Technology Officer | SanityTurbopackSentry+34 | — | — | 1 launch · 1 partnership |
| 19 | RareCyte Developer of technologies for the analysis of rare and single cells in the blood 60Funding top 24%Moat top 29%Patents top 32%Growth top 39% All 9 signals ▾Fundingtop 24% Moattop 29% Patentstop 32% Growthtop 39% Innovationtop 41% Markettop 47% Talentbottom 49% Globalbottom 40% Newsbottom 18% Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $114M | 12 mo ago | 54 54 → 61 (+13%) · sector median +17% | Joseph Victor President & CEO | — | — | 266 patents Advanced fluorescence microscopy and spectral imaging hardware for multiplexed cellular analysis | 1 launch |
| 20 | Sherlock Provider of a diagnostic platform for DNA and RNA detection 62Growth top 13%Funding top 22%Talent top 28%Moat top 41% All 9 signals ▾Growthtop 13% Fundingtop 22% Talenttop 28% Moattop 41% Patentsbottom 46% Innovationbottom 41% Marketbottom 39% Globalbottom 37% Newsbottom 34% Growth: Headcount 1 → 33 (+3200%) across vintages · Fresh capital in last 24 mo Funding: Raised $111M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $111M | 12 mo ago | 33 | David Walt Co-Founder | — | — | 5 patents Remote health monitoring systems that detect critical vitals and trigger emergency interventions | — |
| 21 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | 62 | Manish Agarwal Co-Founder | — | — | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 22 | Addition Therapeutics Developer of RNA-mediated genetic medicines 42Funding top 22%Talent top 38%Moat top 42%Market bottom 40% All 5 signals ▾Fundingtop 22% Talenttop 38% Moattop 42% Marketbottom 40% Globalbottom 36% Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $106M | 6 mo ago | — | Kathleen Collins Founder | — | — | — | — |
| 23 | Strand Therapeutics Provider of platform to deliver mRNA therapeutics for multi functional treatments 64Growth top 13%Funding top 24%Moat top 31%News top 41% All 7 signals ▾Growthtop 13% Fundingtop 24% Moattop 31% Newstop 41% Talenttop 41% Globalbottom 39% Marketbottom 38% Growth: Headcount 16 → 47 (+194%) across vintages · Fresh capital in last 24 mo Funding: Raised $103M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $103M | 12 mo ago | 47 | Tasuku Kitada Co-founder | — | — | — | 2 awards |
| 24 | Applied DNA Sciences Developer of botanical-DNA based security and authentication solutions 24Funding top 24%Product top 24%Tech top 40%Innovation bottom 48% All 10 signals ▾Fundingtop 24% Producttop 24% Techtop 40% Innovationbottom 48% Globalbottom 37% Marketbottom 36% Newsbottom 35% Moatbottom 33% Fin. healthbottom 29% Growthbottom 25% Funding: Raised $98.6M across 17 rounds · 17 rounds over 21 yrs (0.8/yr) Product: 1 product launch event in 12 mo · 7 distinct product lines rank vs industry peers · Fliar Intelligence Index 24/100 | $99M | 8 mo ago | 55 55 → 49 (-11%) · sector median +17% | — | WordPressMySQLPHP+23 | — | — | — |
| 25 | Cleveland Diagnostics Developer of diagnostics technology to detect cancer in early stage 53Funding top 21%Moat top 31%Growth top 35%Tech top 39% All 8 signals ▾Fundingtop 21% Moattop 31% Growthtop 35% Techtop 39% Talentbottom 49% Globalbottom 37% Marketbottom 36% Newsbottom 22% Funding: Raised $96.8M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 53/100 | $97M | 8 mo ago | 40 | Arnon Chait President And Ceo | Squarespace CommerceSquarespaceSentry+25 | — | — | 1 award |
| 26 | Aspira Women's Health Provider of diagnostic solution for ovarian malignancy in women 32Funding top 29%Tech top 46%Market bottom 46%Fin. health bottom 36% All 7 signals ▾Fundingtop 29% Techtop 46% Marketbottom 46% Fin. healthbottom 36% Growthbottom 35% Globalbottom 30% Newsbottom 21% Funding: Raised $96.7M across 8 rounds · 8 rounds over 16 yrs (0.5/yr) Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 32/100 | $97M | 9 mo ago | 85 85 → 60 (-29%) · sector median +17% | — | WordPressApple iCloud MailMySQL+25 | — | — | 2 partnerships |
| 27 | Antheia Genetically engineered yeast cells to produce medicinal products 64Funding top 20%Patents top 25%Moat top 28%Innovation top 34% All 12 signals ▾Fundingtop 20% Patentstop 25% Moattop 28% Innovationtop 34% Producttop 35% Growthtop 36% Talenttop 40% Techtop 45% Newstop 45% Partnerstop 45% Globalbottom 47% Marketbottom 45% Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $96M | 4 mo ago | 50 50 → 66 (+32%) · sector median +17% | Christina Smolke Co-Founder & CEO | WordPressMySQLPHP+28 | 4 signals Leadership · Funding | 82 patents Biotechnological production and optimization of opioid alkaloids (benzylisoquinoline and morphinan) | 2 job openings |
| 28 | Solid Biosciences Developer of gene therapy platform for Duchenne muscular dystrophy 53Patents top 20%Funding top 24%Innovation top 31%Tech top 33% All 10 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 31% Techtop 33% Moattop 38% Newstop 48% Marketbottom 49% Growthbottom 44% Globalbottom 42% Fin. healthbottom 32% Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $92M | 3 mo ago | 101 | — | WordPressApple iCloud MailMySQL+22 | 4 signals ▼33% Earnings · Funding · Leadership | 60 patents AAV vector manufacturing and formulation for cardiac gene therapies | — |
| 29 | Mirvie Provider of non-invasive diagnostic tests for pregnant women 69Growth top 20%Funding top 21%Patents top 24%Talent top 28% All 9 signals ▾Growthtop 20% Fundingtop 21% Patentstop 24% Talenttop 28% Innovationtop 32% Moattop 36% Techtop 46% Globalbottom 40% Marketbottom 35% Growth: Headcount 23 → 35 (+52%) across vintages · Fresh capital in last 24 mo Funding: Raised $90.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $90M | 11 mo ago | 35 35 → 41 (+17%) · sector median +17% | Mads Melbye Co-Founder | WebflowReactTypekit+21 | — | 49 patents Non‑invasive prenatal diagnostics via methylation and RNA biomarkers for pregnancy monitoring | — |
| 30 | Rgenta Developer of RNA-based therapeutics for multiple disorders 32Talent top 28%Funding top 29%Moat top 39%Global bottom 39% All 6 signals ▾Talenttop 28% Fundingtop 29% Moattop 39% Globalbottom 39% Marketbottom 28% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $90.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $90M | 12 mo ago | 11 | Zhiping Weng Co-Founder | — | — | — | — |
| 31 | Volastra Developer of therapeutics for cancer treatment 40Funding top 24%Talent top 28%Moat top 39%Tech bottom 48% All 6 signals ▾Fundingtop 24% Talenttop 28% Moattop 39% Techbottom 48% Globalbottom 37% Marketbottom 31% Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $87M | 9 mo ago | 21 21 → 41 (+95%) · sector median +17% | Samuel Bakhoum Co-Founder | WordPressApple iCloud MailMicrosoft 365+24 | — | — | 1 job opening |
| 32 | Ansa Biotechnologies Provider of DNA synthesis technology using enzymes 74Growth top 26%Funding top 27%Patents top 27%Moat top 32% All 11 signals ▾Growthtop 26% Fundingtop 27% Patentstop 27% Moattop 32% Innovationtop 33% Newstop 38% Producttop 40% Markettop 41% Techtop 43% Talenttop 45% Globalbottom 47% Growth: Headcount 159 → 253 (+59%) across vintages · Fresh capital in last 24 mo Funding: Raised $82.0M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $82M | 8 mo ago | 253 | Sebastian Palluk Co-Founder & CTO | WordPress Block EditorWordPressApple iCloud Mail+27 | 3 signals Funding · Leadership | 32 patents Enzymatic nucleic acid synthesis and polymerase engineering for synthetic biology applications | 1 job opening · 1 award |
| 33 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | 45 | Dave Mullarkey Chief Executive Officer | — | — | — | — |
| 34 | Cartography Biosciences Provider of a platform to discover immunotherapeutics 24Funding top 23%Moat top 31%News top 39%Talent bottom 49% All 6 signals ▾Fundingtop 23% Moattop 31% Newstop 39% Talentbottom 49% Globalbottom 37% Marketbottom 27% Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $57M | 1 mo ago | 10 | Howard Chang Co-Founder | — | — | — | — |
| 35 | ReviR Therapeutics Developer of RNA-based therapeutics for multiple diseases 35Funding top 26%AI top 45%Moat top 47%Talent bottom 49% All 8 signals ▾Fundingtop 26% AItop 45% Moattop 47% Talentbottom 49% Marketbottom 36% Globalbottom 36% Techbottom 31% Newsbottom 18% Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | 29 | Yang Li Co-Founder | UbuntuElement UIVue.js+6 | — | — | 1 partnership |
| 36 | BridGene Biosciences Developer of small-molecule drugs for the treatment of cancer 69Growth top 20%Patents top 23%Funding top 24%Innovation top 26% All 8 signals ▾Growthtop 20% Patentstop 23% Fundingtop 24% Innovationtop 26% Moattop 28% Talenttop 38% Globalbottom 40% Marketbottom 36% Growth: Headcount 15 → 25 (+67%) across vintages · Fresh capital in last 24 mo Patents: 44 patents matched (strict assignee match) · 35 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 8 mo ago | 25 25 → 31 (+24%) · sector median +17% | Irene Yuan Co-Founder & Executive Vice President | — | — | 44 patents Small-molecule kinase and YAP/TAZ-TEAD inhibitors for targeted cancer therapy | — |
| 37 | Kytopen Developer of gene delivery systems for cell therapy 50Funding top 21%Talent top 28%Moat top 32%Patents top 33% All 8 signals ▾Fundingtop 21% Talenttop 28% Moattop 32% Patentstop 33% Innovationtop 36% Globalbottom 40% Marketbottom 28% Newsbottom 22% Funding: Raised $43.1M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $43M | 2 mo ago | 12 12 → 27 (+125%) · sector median +17% | Cullen Buie Co-Founder | — | — | 31 patents Automated electro‑mechanical transfection systems for gene and cell delivery | — |
| 38 | Affinity Biosensors Developer of rapid antimicrobial susceptibility testing devices for life sciences 27Funding top 27%Moat top 31%Talent bottom 49%Patents bottom 46% All 7 signals ▾Fundingtop 27% Moattop 31% Talentbottom 49% Patentsbottom 46% Innovationbottom 39% Globalbottom 36% Marketbottom 34% Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $31M | 2 mo ago | 21 | Ken Babcock CEO | — | — | 12 patents Rapid antimicrobial susceptibility testing via resonant mass and microchannel sensor technologies | — |
| 39 | Kiyatec Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to… 32Product top 25%Moat top 32%Funding top 37%Innovation top 48% All 9 signals ▾Producttop 25% Moattop 32% Fundingtop 37% Innovationtop 48% Patentstop 50% Marketbottom 40% Globalbottom 37% Techbottom 36% Newsbottom 21% Product: 5 distinct product lines · Company stage: Series C Moat: Editorial + unicorn rating 7/10 · IP moat: 36 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $29M | 7 mo ago | 28 | — | — | — | 36 patents In vitro cancer drug screening platforms using 3D tumor bioreactors for dosing optimization | — |
| 40 | Phylos Bioscience Developer of cannabis F1 hybrid seeds and natural THC products 42Funding top 26%Moat top 39%Talent top 41%Partners top 45% All 9 signals ▾Fundingtop 26% Moattop 39% Talenttop 41% Partnerstop 45% Techtop 46% Marketbottom 46% Growthbottom 38% Globalbottom 37% Newsbottom 17% Funding: Raised $28.2M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 42/100 | $28M | 5 mo ago | 61 61 → 50 (-18%) · sector median +17% | Nishan Karassik Chief Innovation Officer | PrismicNode.jsNginx+14 | — | — | 4 launchs |
| 41 | Solarea Bio Innovating microbial solutions for human health, focusing on aging well 29Funding top 29%Moat top 39%Tech top 43%News top 44% All 7 signals ▾Fundingtop 29% Moattop 39% Techtop 43% Newstop 44% Talentbottom 49% Globalbottom 36% Marketbottom 29% Funding: Raised $27.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $27M | 7 mo ago | 24 | Gerardo Toledo Co-Founder & CEO | SanityNode.jsHeadless UI+9 | — | — | — |
| 42 | Cofactor Genomics Developer of diagnostic assays using RNA sequencing 48Funding top 30%Moat top 32%Growth top 35%Tech top 39% All 11 signals ▾Fundingtop 30% Moattop 32% Growthtop 35% Techtop 39% AItop 45% Patentstop 46% Talentbottom 49% Innovationbottom 47% Globalbottom 40% Marketbottom 22% Newsbottom 18% Funding: Raised $26.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $26M | 6 mo ago | 9 | Jarret Glasscock Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+35 | — | 24 patents Patents concentrated in computing, sensing & instrumentation | — |
| 43 | Think Bioscience Provider of synthetic biology platform to develop small-molecule therapeutics 22Funding top 30%Talent top 38%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 30% Talenttop 38% Moattop 39% Globalbottom 39% Techbottom 30% Marketbottom 28% Funding: Raised $26.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 22/100 | $26M | 4 mo ago | 21 21 → 31 (+48%) · sector median +17% | Jerome Fox Co-Founder & CEO | WordPressMySQLPHP+11 | — | — | — |
| 44 | Arpeggio Provider of drug discovery platform for the treatment of cancer 24Funding top 27%Moat top 31%Talent top 38%Global bottom 37% All 6 signals ▾Fundingtop 27% Moattop 31% Talenttop 38% Globalbottom 37% Marketbottom 25% Newsbottom 22% Funding: Raised $25.4M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $25M | 7 mo ago | 8 | Laura Norris Co-Founder | — | — | — | — |
| 45 | 4D Path Developer of precision medicines for the treatment of cancer 35Talent top 28%Patents top 31%Funding top 37%Moat top 38% All 8 signals ▾Talenttop 28% Patentstop 31% Fundingtop 37% Moattop 38% Innovationtop 41% Techbottom 38% Globalbottom 37% Marketbottom 23% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 46 patents matched (strict assignee match) · 15 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $17M | 1 mo ago | 10 | Rodrigo Navarro Co-Founder & CEO & President | WordPressMySQLPHP+16 | — | 46 patents Lipid‑nanoparticle delivery systems for malaria vaccines and encapsulated therapeutics | 2 partnerships |
| 46 | Genialis Developer of end-to-end bioinformatics software solutions 53Funding top 33%Growth top 35%Moat top 37%Patents top 38% All 10 signals ▾Fundingtop 33% Growthtop 35% Moattop 37% Patentstop 38% Innovationtop 39% Talenttop 41% Producttop 46% Techtop 50% Globalbottom 44% Marketbottom 35% Funding: Raised $15.3M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $15M | 6 mo ago | 35 | Rafael Rosengarten Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+23 | — | 17 patents Patents concentrated in computing, sensing & instrumentation | 1 launch |
| 47 | Seek Labs Developer of a technology for the treatment and diagnostics of infectious diseases. 53AI top 15%Patents top 27%Innovation top 28%Moat top 32% All 9 signals ▾AItop 15% Patentstop 27% Innovationtop 28% Moattop 32% Fundingtop 33% Talentbottom 49% Techbottom 44% Globalbottom 31% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) Patents: 48 patents matched (strict assignee match) · 30 filings since 2022 vs 12 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $14M | 3 mo ago | 27 | Jared Bauer CEO | WordPressMySQLPHP+26 | — | 48 patents Molecular diagnostics and CRISPR-based nucleic acid testing for veterinary disease detection | — |
| 48 | GenoPalate Provider of personalized diet plans based on the genetic disposition 48Tech top 27%Talent top 28%Growth top 35%Funding top 40% All 9 signals ▾Techtop 27% Talenttop 28% Growthtop 35% Fundingtop 40% Productbottom 48% Customersbottom 40% Globalbottom 29% Marketbottom 24% Newsbottom 18% Tech: 67 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 48/100 | $12M | 4 mo ago | 15 | — | Cart FunctionalityShopifySentry+57 | — | — | 1 partnership |
| 49 | NovaScan Developer of diagnostic platform technology for cancer detection 32Innovation top 26%Patents top 26%Moat top 32%Funding top 36% All 8 signals ▾Innovationtop 26% Patentstop 26% Moattop 32% Fundingtop 36% Talentbottom 49% Globalbottom 40% Marketbottom 24% Techbottom 24% Innovation: 57 patents (top 28% of patent-holders) · 40 filings since 2022 vs 17 in 2017-21 Patents: 57 patents matched (strict assignee match) · 40 filings since 2022 vs 17 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $8M | 1 mo ago | 16 | Craig Davis President and CEO | WordPressMySQLPHP+11 | — | 57 patents Intraoperative cancer detection and tissue characterization via impedance-based medical devices | — |
| 50 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 1 mo ago | 5 | — | Google MapsBootstrapNginx+6 | — | — | 1 job opening |
Top 12 Genomics companies in United States
#1
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#2
Public · The Woodlands, Texas · founded 1995 · 135 employees$381.3Mraised▾
Public · The Woodlands, Texas · founded 1995 · 135 employees
Developer of small molecule drugs for diffrent health diseases. It uses gene trapping and gene targeting technologies to discover new drug targets and develop small molecule drugs across therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Fliar Intelligence Index™ 76how this company ranks against its industry peers
Funding
top 20%Patents
top 24%Talent
top 28%Growth
top 30%Tech
top 35%Innovation
top 40%Funding: Raised $381M across 9 rounds · 9 rounds over 28 yrs (0.3/yr) · Last round Post IPO (Feb 2026)
Patents: 1,211 patents matched (strict assignee match) · 94 filings since 2022 vs 219 in 2017-21 · Latest publication 2026
Talent: Analyst team rating 5/5 · 2 named leaders on record
Audience (LinkedIn): 24k LinkedIn followers — 3.5% of this cohort's audience
Funding rounds
- Feb 2026Post IPO$55.7M
- Aug 2022Post IPO$42.9M
- Mar 2017Post IPO$10.5M
- Dec 2014Post IPO$4.7M
Founders & team
Investors
Bay City Capital, New Enterprise Associates, Military Health, BCM Technologies, Genechem
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesApple Icloud MailCore-JsDocusign
#3
Public · Redwood City, California · founded 2012 · 1351 employees$557.5Mraised▾
Public · Redwood City, California · founded 2012 · 1351 employees
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Fliar Intelligence Index™ 90how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Moat
top 19%Market
top 23%Tech
top 23%Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 · Latest publication 2026
Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (Nov 2025)
Innovation: 996 patents (top 3% of patent-holders) · 615 filings since 2022 vs 346 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 275k LinkedIn followers — 39.9% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Cancer Research UK Science and Innovation and The Royal Marsden NHS Foundation Trust) announced in 12 mo
Funding rounds
- Nov 2025Post IPO$350M
- Nov 2020Post IPO$1B
- Aug 2017Series E$360M
- Jan 2016Series D$100M
Founders & team
Investors
Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8, Heritage Group
Tech stack
Amazon Web ServicesAosApache Http ServerApple Icloud MailBootstrapBugherd
#4
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Series A · San Francisco, California · founded 2021 · 62 employees
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Patents
top 38%Talent
top 38%Market
top 46%Innovation
top 49%Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents · Soonicorn
Patents: 15 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Accounts Payable Clerk
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
Founders & team
Investors
F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp
#5
Public · Durham, North Carolina · founded 2006 · 236 employees$135.7Mraised▾
Public · Durham, North Carolina · founded 2006 · 236 employees
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Product
top 19%Funding
top 21%Moat
top 32%Patents
top 36%News
top 38%Market
top 39%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 6/10 · IP moat: 68 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 3.5% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Post IPO$7.5M
- Jun 2022Post IPO$75M
- Mar 2019Conventional Debt$39.5M
- Jun 2018Series B$110M
Investors
NIST, NIH, North Carolina, Treasury, VenBio, Baxter
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#6
Series D · San Diego, California · founded 2016 · 45 employees$70Mraised▾
Series D · San Diego, California · founded 2016 · 45 employees
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 36%Market
top 50%Talent
bottom 49%Global
bottom 36%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (May 2026)
Market: 45 employees (top 39% of Life Sciences)
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- May 2025Series C$21.8M
- May 2021Series C$70M
Founders & team
Investors
Pathology Asia Holdings
#7
Series B · Baltimore, Maryland · founded 2019 · 197 employees$331.6Mraised▾
Series B · Baltimore, Maryland · founded 2019 · 197 employees
Provider of DNA sequencing for cancer detection. The company's platform uses artificial intelligence and whole genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 17%Patents
top 24%AI
top 28%Moat
top 28%Innovation
top 32%Talent
top 42%Funding: Raised $332M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Conventional Debt (Dec 2025)
Patents: 52 patents matched (strict assignee match) · 52 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
AI: Holds AI/ML patents (G06N-family CPC) · Product described with: artificial intelligence
Audience (LinkedIn): 20k LinkedIn followers — 2.9% of this cohort's audience · 29 engagements/post (1.5× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Data Scientist, Computational Biology
Activity (LinkedIn): 1 partnerships · 3 awards (incl. OSF HealthCare) announced in 12 mo
Funding rounds
- Dec 2025Conventional Debt$34.3M
- Jun 2024Series B—
- Jul 2022Series B$225M
- Jan 2021Series A$101.1M
Founders & team
Investors
Merck Global Health Innovation Fund, DFJ Growth, Lilly, Point72, Brown Advisory, Point Field Partners
#8
Public · Cambridge, Massachusetts · founded 2014 · 101 employees$92.5Mraised▾
Public · Cambridge, Massachusetts · founded 2014 · 101 employees
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 20%Funding
top 24%Innovation
top 31%Tech
top 33%Moat
top 38%News
top 48%Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 · Latest publication 2026
Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Innovation: 60 patents (top 27% of patent-holders) · 43 filings since 2022 vs 17 in 2017-21
Funding rounds
- Mar 2026Post IPO$240M
- Jan 2024Post IPO$108.9M
- Dec 2020Post IPO$90M
- Oct 2020Post IPO$40M
Investors
RA Capital Management, RTW Investments, Foresite Capital, Perceptive Advisors, Janus Henderson Investors, Biogen
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#9
Series B · Foster City, California · founded 2020 · 10 employees$57Mraised▾
Series B · Foster City, California · founded 2020 · 10 employees
Provider of a platform to discover immunotherapeutics. It provides a platform that combines computational and experimental techniques to profile antigens of cancerous cells and identify targets for immuno-oncology treatments.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 23%Moat
top 31%News
top 39%Talent
bottom 49%Global
bottom 37%Market
bottom 27%Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
News: 2 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- May 2026Series B—
- Oct 2025Series B$67M
- Jul 2022Series A$57M
Founders & team
Investors
8VC, Dren Bio, Hexagon, Myeloid Therapeutics, Alloy Therapeutics, Andreessen Horowitz
#10
Series A · San Francisco, California · founded 2021 · 29 employees$54Mraised▾
Series A · San Francisco, California · founded 2021 · 29 employees
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%AI
top 45%Moat
top 47%Talent
bottom 49%Market
bottom 36%Global
bottom 36%Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series A (Apr 2026)
AI: Product described with: machine learning
Moat: Editorial + unicorn rating 3/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. CureCMT) announced in 12 mo
Funding rounds
- Apr 2026Series A—
- Nov 2025Grant (prize money)$4.6M
- Jul 2024Series A$30M
- Jan 2022Seed$20M
Founders & team
Investors
Lapam Capital, CDH, 5Y Capital, Yael Capital, Cmtrf, XtalPi
Tech stack
Core-JsElement UiGoogle WorkspaceLodashNginxSwiper
#11
Series C · San Diego, California · founded 2018 · 94 employees$224Mraised▾
Series C · San Diego, California · founded 2018 · 94 employees
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 17%Patents
top 23%Moat
top 28%Innovation
top 33%Growth
top 35%News
top 45%Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Series C (Nov 2025)
Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 57 patents · Soonicorn
Audience (LinkedIn): 13k LinkedIn followers
Funding rounds
- Nov 2025Series C$115M
- Dec 2022Conventional Debt$40M
- May 2022Series B$147.5M
- Apr 2020Series A$70M
Founders & team
Investors
Orbimed, Arch Venture Partners, Frazier Healthcare Partners, Domain Associates, S32, Google Ventures
Tech stack
CloudflareCloudflare Bot ManagementCore-JsGeneratepressGeneratepress Gp PremiumGodaddy
#12
Series C · Palo Alto, California · founded 2013 · 50 employees$96.4Mraised▾
Series C · Palo Alto, California · founded 2013 · 50 employees
Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Patents
top 25%Moat
top 28%Innovation
top 34%Product
top 35%Growth
top 36%Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) · Last round Series C (Jan 2026)
Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 8/10 · IP moat: 82 patents · Soonicorn
Audience (LinkedIn): 10k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Associate Director of Global Quality, Senior Quality Control Manager
Funding rounds
- Jan 2026Series C$24M
- Jun 2025Series C$56M
- Jul 2024Series B$6M
- Jun 2022Venture Debt$40M
Founders & team
Investors
Viking Global Investors, Sherpalo Ventures, In-Q-Tel, Echo, Oxford Finance, SVB
Tech stack
BabelCloudflareCloudflare Bot ManagementCookieyesCore-JsElementor
Funding & investor landscape
$64.9Btotal disclosed funding
1,331companies funded
5,584disclosed rounds
9rounds last 90 days
Most active investors
Notable founders
Jim Collins
Co-Founder · Senti Bio
Wilson Wong
Co-Founder · Senti Bio
Ivan Cheung
Board of Directors · Lexicon Pharmaceuticals
Ray Debbane
Chairman of Board · Lexicon Pharmaceuticals
Amirali Talasaz
Co-founder and Co-Chief Executive Officer · Guardant Health
Roberto Mignone
Board of Directors · Guardant Health
Manish Agarwal
Co-Founder · Adela
Scott Bratman
Co-Founder · Adela
Dave Mullarkey
Chief Executive Officer · ClearNote Health
Victor Velculescu
Founder and Board of Directors · Delfi Diagnostics
Susan Tousi
CEO · Delfi Diagnostics
Howard Chang
Co-Founder · Cartography Biosciences
Prism market signals · United States · country-scoped Prism corpus, 1,273,702 docs
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
research sentiment over time
200820182029
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 41% → 46% across 2008–2029.
top research entities
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
leading researchers
Glen Charles Ritschel · Claude · Stylianos Chatzimanolis · Giannis Bolanakis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Yue Ma
▲
Breakthroughs5,029 · 38%
▼ 39%→38% share
▲1.0× share momentum0 median citations85% since 2021mostly methods-led
Transcriptome breakthroughs are surging — U.S. papers jumped from 25 to 436, with interpretability emerging as a brand-new focus.
rising sub-themes (early→recent)
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
Newly emergingPattern recognition (psychology) 0→57 · Interpretability 0→50 · Limiting 0→47
Landmark Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 97,164 cites
◆
Advancements3,749 · 29%
▲ 21%→30% share
▲1.4× share momentum0 median citations90% since 2021mostly empirical
Biomarker advancement research is intensifying — papers rose from 2 to 208, alongside newly emerging precision medicine work (86 papers).
rising sub-themes (early→recent)
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
Newly emergingPrecision medicine 0→86 · Pathogenesis 0→49 · Receptor 0→42
Landmark limma powers differential expression analyses for RNA-sequencing and microarray studies · 41,828 cites
▼
Concerns2,105 · 16%
▼ 18%→16% share
▼0.9× share momentum0 median citations85% since 2021mostly reviews
Disease-related concerns are escalating — papers grew from 27 to 311, with immunotherapy newly flagged as a concern (56 papers).
rising sub-themes (early→recent)
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Newly emergingImmunotherapy 0→56 · Narrative review 0→36 · Mutation 0→33
Landmark The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia · 10,090 cites
RESEARCH HOTSPOTS · United States
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1143 · +0.51
New York807 · +0.46
SF Bay Area683 · +0.57
Philadelphia330 · +0.44
San Diego298 · +0.56
Los Angeles287 · +0.42
Chicago284 · +0.51
Seattle244 · +0.54
Ann Arbor218 · +0.45
Atlanta215 · +0.44
PATENT SIGNAL · United States
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
246 filings64 assigneespeak 44/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Baluch Mohamed Khoso7
- Genomsys7
- Microsoft6
- Contamination Source Identificat5
Common questions
How many Genomics companies are there in United States?
Radar tracks 2583 indexable Genomics companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Genomics companies in United States?
The Genomics companies in United States on this list have raised a combined $64.9B in disclosed equity funding across 1331 funded companies.
Which is the highest-funded Genomics company in United States?
Freenome Health is the highest-funded Genomics company in United States, with $1.4B in disclosed equity funding.
How many Genomics companies in United States are funded?
1331 of the 2583 Genomics companies in United States on this list have disclosed at least one equity funding round.
How many Genomics unicorns are there in United States?
13 Genomics companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Genomics companies?
The most active investors in United States Genomics companies on this list include HHS, National Science Foundation, NIH, Alexandria, Arch Venture Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.